Online Inquiry
AKT1 (E17K/+) Cell Line
SPL-00186
| Size | Price |
| 1 Unit | Online Inquiry |
| Description |
|---|
| AKT1 (E17K/+) |
| Target Information | |
|---|---|
| Target Name | Akt |
| Gene Abbr. | AKT1 |
| Gene ID | 207 |
| Full Name | AKT serine/threonine kinase 1 |
| Alias | AKT, PKB, PKB-ALPHA, PRKBA, RAC |
| Species | Human |
| Genomic Locus | 14q32.32 |
| Introduction | The serine-threonine protein kinase encoded by the AKT1 gene is catalytically inactive in serum-starved primary and immortalized fibroblasts. AKT1 and the related AKT2 are activated by platelet-derived growth factor. The activation is rapid and specific, and it is abrogated by mutations in the pleckstrin homology domain of AKT1. It was shown that the activation occurs through phosphatidylinositol 3-kinase. In the developing nervous system AKT is a critical mediator of growth factor-induced neuronal survival. Survival factors can suppress apoptosis in a transcription-independent manner by activating the serine/threonine kinase AKT1, which then phosphorylates and inactivates components of the apoptotic machinery. Mutations in this gene have been associated with the Proteus syndrome. Multiple alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, Jul 2011]. |
| Product Details | |
|---|---|
| Cell Line Model | MCF10A |
| Genotype | AKT1 (E17K/+) |
| Description | AKT1 (E17K/+) |
| Parental ATCC ID | CRL-10317 |
| STR Profile | Amelogenin: X; CSF1PO: 10,12; D13S317: 8,9; D16S539: 11,12; D5S818: 10,13; D7S820: 10,11; THO1: 8,9.3; TPOX: 9,11; vWA: 15,17; ATCC |
| Disease | Epithelial |
| Tissue | Breast |
| Gender | Female |
| Key Endogenous Mutations | none listed |
| CVT Selection Condition | No antibiotic resistance |
| Cell Number | 1x10^6 |
| Handling Specifications | |
|---|---|
| Revival | Cells are cultured as a monolayer at 37°C in a humidified atmosphere with 5% CO2. Cells should be passaged every 3-5 days. Split at 80-90% confluency, approximately 1:6-1:10. |
| Culture Medium | DMEM/F-12 including 2.5 mM L-glutamine and 15 mM HEPES, supplemented with 5% horse serum, 10 µg/mL insulin, 20 ng/mL hEGF, 0.5 µg/mL hydrocortisone, 0.1 µg/mL cholera toxin. |
| Growth Properties | Cells are cultured as a monolayer at 37°C in a humidified atmosphere with 5% CO2. Cells should be passaged every 3-5 days. Split at 80-90% confluency, approximately 1:6-1:10. |
| Freeze Medium | Complete growth media 45% + USDA approved FBS 50% + DMSO 5% |
| Biosafety Level | BSL-1 |
| Disclaimer | This product is classified under IATA regulations as a GMMO (genetically modified micro-organism) and will ship as UN3245. If applicable, ensure facility meets all requirements per local and country regulations. |
For research use only. Not intended for any clinical use. No products from CD BioSciences may be resold, modified for resale or used to manufacture commercial products without prior written approval from CD BioSciences.